CLEARWATER, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and wellness, is pleased to confirm the filing, after the market close, of its Quarterly Report (Form 10-Q), for the financial period, ending on December 31, 2025. The Company reported $548,315 in Revenue for its fiscal second quarter of 2025. This performance was result of a successful strategic s ...

Core Viewpoint - Teladoc Health has experienced a significant decline in market value, losing over 98% in the past five years, and is struggling to regain its previous success during the pandemic [1] Industry Overview - Demand for telemedicine services peaked during the pandemic, with usage increasing from 5% pre-pandemic to 42.1% during, and settling at 21.8% post-pandemic, which is still above pre-2019 levels [3] - The telemedicine sector is facing intense competition, particularly from larger corporations like Amazon, which poses challenges for Teladoc's growth, especially in its virtual therapy service, BetterHelp [4] Company Initiatives - Teladoc is attempting to address competition by seeking third-party coverage for BetterHelp to enhance demand and has launched new services such as continuous health monitoring and chronic care [5] - The company is also expanding internationally, with international revenue growing faster than domestic revenue in recent quarters [5] Financial Performance - Despite efforts to grow, Teladoc's revenue is increasing slowly, and the company is currently operating at a loss, with concerns that international expansion may lead to similar challenges as faced domestically [7] - The company has not yet secured broad health insurance coverage for its therapy services, even after acquiring UpLift, which has 100 million covered lives, indicating that third-party coverage does not guarantee demand or revenue [8] Future Outlook - The outlook for Teladoc appears bleak, with significant challenges ahead, and the stock price recently trading at $4.90, raising concerns that it could approach $0 in the next five years [9]

Core Viewpoint - Teladoc Health, once thriving during the COVID-19 pandemic, is now facing stagnant and declining revenue, leading to concerns about its long-term viability as a company [1][12]. Company Overview - Founded in 2002, Teladoc Health specializes in remote medical appointments and had a successful IPO in 2015, experiencing steady share price growth until the pandemic [2]. - The company's stock price surged 224% from approximately $81 per share in late 2019 to a peak of $263 per share in January 2021 [4]. Current Financial Performance - By the end of 2023, Teladoc's share price had plummeted to $21, representing a 92% decrease from its peak [5]. - As of the latest data, the stock trades around $5, with a market capitalization of $861 million [6][7]. - Revenue for 2023 was reported at $2.6 billion, which is projected to decline by 1% to $2.5 billion in 2024, with further decreases anticipated in subsequent quarters [10]. Competitive Landscape - Teladoc faces significant competition from other telemedicine providers and traditional in-person medical services, with 71% of patients preferring in-person visits according to the National Institutes of Health [8][9]. - The company has struggled to maintain its market position as telemedicine becomes less dominant post-pandemic [9]. Profitability Challenges - Teladoc has never achieved profitability, with a net profit margin of negative 21% during its peak in 2021, improving slightly to negative 8.8% but still indicating ongoing financial struggles [11]. - The company is characterized by a lack of growth and profitability, raising concerns about its future sustainability [12].

Core Insights - The global medical devices market is projected to grow from US$ 517.86 billion in 2024 to US$ 905.56 billion by 2033, with a CAGR of 6.4% from 2025 to 2033 [1][2] Market Growth Drivers - The market is experiencing dynamic growth due to increased focus on personalized care and early diagnostics, with significant investments in wearable sensors, robotic surgery systems, and advanced imaging tools [2] - The proliferation of digitally connected devices is evident, with an estimated 504 million wearable health monitors expected to ship worldwide in 2023 [2][4] - The US FDA granted clearances to over 2,900 novel medical technologies in the past year, indicating a strong innovation pipeline [2][4] Regional Insights - The United States, Germany, and China dominate global production, with the US having over 6,500 licensed device manufacturers in 2023 [3] - Germany exported advanced surgical instruments worth nearly US$ 28 billion last year, while China's output of single-use medical devices reached 65 billion units [3] - Asia Pacific is expected to register the highest growth rate of 7.1%, driven by strong manufacturing bases and supportive government policies [9][10] Product Innovations - Wearable healthcare solutions are redefining chronic condition management, with 504 million wearable shipments in 2023, including devices for heart rate tracking and continuous glucose monitoring [4] - The introduction of 1,200 new smartphone-linked ECG patches this year enhances diagnostic precision for cardiologists [4] - Over 40 new remote patient monitoring devices achieved CE Mark approval in Europe in the first half of 2023, reflecting robust acceptance of telemedicine solutions [8] Market Segmentation - Key product categories include diagnostic devices, patient monitoring devices, imaging systems, and consumables [12][13] - Major applications span across cardiology, orthopedics, oncology, and respiratory care [15][16] Major Players - Notable companies in the medical devices market include 3M Co., Abbott Laboratories, Johnson & Johnson, Medtronic Inc., and Siemens Healthcare [11]

Core Viewpoint - The agreement between CFFM and Pulsenmore marks a significant advancement in prenatal care, enabling remote monitoring through home ultrasound services, which enhances patient access and reduces unnecessary visits to diagnostic centers [1][5]. Company Overview - Pulsenmore is focused on transforming maternal health with home-use ultrasound technology that connects mothers and healthcare providers remotely, aiming to improve access and continuity of prenatal care [6]. - CFFM is a prenatal diagnostic center in California that specializes in high-risk pregnancies, managing approximately 1,500 pregnancies annually across two locations in the Los Angeles area [3]. Technological Innovation - Pulsenmore's ultrasound system is designed to empower expectant mothers by providing safe, guided access to ultrasound imaging from home or work, while maintaining close clinician involvement throughout the process [4]. - The collaboration with CFFM will facilitate a remote pregnancy monitoring model that prioritizes patient needs, demonstrating the potential of home-based ultrasound as a routine part of medical care [6]. Market Potential - The agreement with CFFM represents Pulsenmore's first commercial venture in the United States, following recent FDA clearance, and is seen as a crucial step in the company's strategic plan to tap into the U.S. market, which holds significant clinical and business opportunities [5].

Core Viewpoint - The agreement between Pulsenmore and Clalit aims to revolutionize fertility care by allowing patients to perform follicular monitoring scans from home, enhancing convenience and maintaining clinical oversight [1][4]. Group 1: Agreement Details - Pulsenmore and Clalit will establish an end-to-end clinical service through Beilinson NEXT, enabling eligible patients to conduct follicular monitoring scans at home with real-time guidance [1]. - The agreement allows both companies to market Pulsenmore FC directly to patients, facilitating access to at-home fertility monitoring [1]. Group 2: Product Overview - Pulsenmore FC is a patient-operated ultrasound device designed for at-home follicular monitoring, transmitting scan data securely to the Beilinson NEXT care team for remote interpretation [3]. - The device aims to reduce the need for frequent in-clinic visits during IVF and fertility preservation cycles, thus minimizing disruption to patients' daily lives [3]. Group 3: Clinical Study Results - A controlled clinical study at Beilinson Medical Center reported a strong safety profile for Pulsenmore FC, showing high concordance between at-home measurements and in-clinic assessments [2]. Group 4: Strategic Vision - Clalit’s CEO emphasized that the new service aligns with their strategic vision of providing medical services from home, ensuring quality comparable to hospital settings [5]. - The service is expected to enhance the experience for women and couples undergoing fertility treatments, addressing the emotional and physical complexities involved [5]. Group 5: Future Developments - Pulsenmore has also supplied Clalit with its physician-supervised home prenatal ultrasound solution, Pulsenmore ES, which has received FDA De Novo authorization [5]. - A binding agreement for an additional 25,000 Pulsenmore ES units over five years has been signed, indicating a commitment to expanding their service offerings [5].

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292711 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) FORM S-1 REGISTRATION STATEMENT 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 75248 (214 ...

I thought what I would do is to do something that a little bit different than talk that you, you know, you hear about space a little bit different than uh otherwise. You know, normally when astronauts go out, we want to talk about what it's like to travel in space and we want to, you know, talk about the liftoff and the spacew walk and all that sort of thing. And what we're going to do today is sort of focus on humans in space and why why should we have humans in space but more importantly what does it take ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Texas 8099 87-3841292 (State or other jurisdiction of (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 7524 ...

As filed with the Securities and Exchange Commission on December 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8000 86-2970927 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 980 N Federal Hwy Suite ...